Taken together, these findings suggest that targeting SERPINB3 based on HPV‐positive HNSCC is a potential strategy to overcome cisplatin resistance in HPV‐negative HNSCC and improves the prognosis of this disease. The gene discussed is SERPINB3; the disease is head and neck squamous cell carcinoma.